First Tracks Biotherapeutics Inc.
Organization details
- Legal name
- First Tracks Biotherapeutics Inc.
- Former names
- Biopharma Company, Inc.
- Ownership
- Public
- Status
- Active
- Sector (GICS)
- Health Care
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- TRAX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0002091349
- EIN
- 39-5003207
Board of directors
-
Daniel Faga · Director · President, CEOSince 2026
-
Dennis M. Fenton · DirectorSince 2026
-
J. Anthony Ware · DirectorSince 2026
-
John A. Orwin · DirectorSince 2026
- Since 2026
- Since 2026
- Since 2026
Chief executives
Board connections
7 of this board's directors also sit on 13 other boards. 12 are in the same sector.
-
AnaptysBio Inc. Same sectorvia Daniel Faga, Dennis M. Fenton, J. Anthony Ware, John A. Orwin, John P. Schmid, Magda Marquet and Rita Jain
-
Arcturus Therapeutics Holdings Inc. Same sectorvia Magda Marquet
-
Avalo Therapeutics Inc. Same sectorvia Rita Jain
-
BlossomHill Therapeutics Inc. Same sectorvia John P. Schmid
-
BridgeBio Oncology Therapeutics Inc. Same sectorvia John P. Schmid
-
Celldex Therapeutics Inc. Same sectorvia Rita Jain
-
Design Therapeutics Inc. Same sectorvia John P. Schmid
- via John P. Schmid
-
Immix Biopharma Inc. Same sectorvia Magda Marquet
-
SAB Biotherapeutics Inc. Same sectorvia Rita Jain
-
TransCode Therapeutics Inc. Same sectorvia Magda Marquet
-
Travere Therapeutics Inc. Same sectorvia John A. Orwin
-
Xeris Biopharma Holdings Inc. Same sectorvia John P. Schmid
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $66,742,277
- 2 sales by 2 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 15, 2026 | John A. Orwin Director | Option exercise | +1,300 | — | — |
| Sep 2, 2026 | J. Anthony Ware Director | Option exercise | +39,265 | $5.74 | $225,381 |
| Sep 2, 2026 | J. Anthony Ware Director | Open-market sale | −39,265 | $44.78 | $1,758,287 |
| Jun 15, 2026 | Rita Jain Director | Option exercise | +7,330 | — | — |
| Jun 15, 2026 | J. Anthony Ware Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | John P. Schmid Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | John A. Orwin Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | Magda Marquet Director | Option exercise | +6,030 | — | — |
| Jun 15, 2026 | Dennis M. Fenton Director | Option exercise | +6,030 | — | — |
| Apr 20, 2026 | EcoR1 Capital, LLC 10% owner | Open-market sale | +4,705,575 | $13.81 | $64,983,991 |
| Apr 20, 2026 | ANAPTYSBIO, INC 10% owner | Other | −100 | — | — |
Peers
Compare boardsOrganizations in the same sector, closest in location and size first.
Questions about First Tracks Biotherapeutics Inc.
Who is the CEO of First Tracks Biotherapeutics Inc.?
Daniel Faga has been First Tracks Biotherapeutics Inc.'s President, CEO since April 2026.
How many directors are on First Tracks Biotherapeutics Inc.'s board?
First Tracks Biotherapeutics Inc.'s board has 7 directors: Daniel Faga, Dennis M. Fenton, J. Anthony Ware, John A. Orwin, John P. Schmid, Magda Marquet and Rita Jain.
Are First Tracks Biotherapeutics Inc. insiders buying or selling shares?
Over the last 12 months, First Tracks Biotherapeutics Inc. insiders made no open-market purchases and sold $66.7 million of shares in 2 sales on the open market, as reported to the SEC on Forms 4 and 5.
Embed this board on your site
Paste this where the board should appear. It always shows the current directors and links back here.
<div data-bod-board="first-tracks-biotherapeutics-inc"></div>
<script src="https://boardofdirectors.review/embed.js" async></script>Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.